Ortho and Thermo Fisher Enter Into Partnership for Quality Control Products
By LabMedica International staff writers Posted on 08 Jul 2021 |
Illustration
Ortho Clinical Diagnostics (Raritan, NJ, USA) has entered into a distribution agreement with Thermo Fisher Scientific Inc. (Waltham, MA, USA) to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions to VITROS System customers worldwide.
The VITROS QC Solutions will provide customers with a combination of Ortho Clinical Diagnostics controls and Thermo Scientific MAS Quality Controls to bring a complete quality control solution to the laboratory. Featuring consolidated, liquid-ready, Gen-Specific Value assignment along with LabLink xL, a web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. VITROS System customers will have access to the unique Gen-Specific Peer Group evaluation, that is currently unavailable through any other quality control program. Paired with the proprietary technologies and benefits only available on VITROS Systems, VITROS QC Solutions improves workflows and drives efficiency, enabling labs to streamline operations without sacrificing quality.
"Ortho continues to bring innovative solutions to market, like our latest VITROS QC Solutions, that allow labs to take charge of their operations with improved ease of use and optimized product utilization – saving them time and money," said Bryan Hanson, Head of Clinical Laboratories Business Unit at Ortho Clinical Diagnostics. "Through this agreement with Thermo Fisher Scientific, we can provide laboratories with better solutions, allowing them to maximize their laboratory productivity."
Related Links:
Ortho Clinical Diagnostics
Thermo Fisher Scientific Inc.
The VITROS QC Solutions will provide customers with a combination of Ortho Clinical Diagnostics controls and Thermo Scientific MAS Quality Controls to bring a complete quality control solution to the laboratory. Featuring consolidated, liquid-ready, Gen-Specific Value assignment along with LabLink xL, a web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. VITROS System customers will have access to the unique Gen-Specific Peer Group evaluation, that is currently unavailable through any other quality control program. Paired with the proprietary technologies and benefits only available on VITROS Systems, VITROS QC Solutions improves workflows and drives efficiency, enabling labs to streamline operations without sacrificing quality.
"Ortho continues to bring innovative solutions to market, like our latest VITROS QC Solutions, that allow labs to take charge of their operations with improved ease of use and optimized product utilization – saving them time and money," said Bryan Hanson, Head of Clinical Laboratories Business Unit at Ortho Clinical Diagnostics. "Through this agreement with Thermo Fisher Scientific, we can provide laboratories with better solutions, allowing them to maximize their laboratory productivity."
Related Links:
Ortho Clinical Diagnostics
Thermo Fisher Scientific Inc.
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus